Suzanne Lentzsch, MD, PhD

Director of the Myeloma & Amyloidosis Service @columbiacancer - Associate Editor @JCO_ASCO-Tweets are my own

[Suzanne Lentzsch, MD, PhD @SLentzsch]

@awechalekar @AlexionPharma @Amyloidosis_ARC @ISA_Amyloidosis Anselamimab was approved in Japan as Amylpave for systemic k-AL on Sept 16th in Japan!

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: 1F10, a novel high-affinity lambda subtype-specific amyloid-binding antibody enhances phagocytosis of amyloid; demonstrates robust activity in AL amyloidoma mouse model, accelerating resolution of lambda amyloid fibrils: https://t.co/bIgtDiiVNL. #alsm

[awechalekar @awechalekar]

The global first step towards an anti-fibril in
Kappa AL Amyloidosis- anselamimab gets positive recommendations for approval in Japan - great work @AlexionPharma @SLentzsch @Amyloidosis_ARC @ISA_Amyloidosis

[Raj Chakraborty @rajshekharucms]

Incredible 2-year PFS with Ramantamig in a ~95% CD38-refractory and 100% triple-class exposed population! These results are substantially superior compared to single-agent BCMA BsAbs and BCMA or GPRC5D CAR Ts in similar population. Based on these results, its plausible that we will see a near-flat PFS curve with Ram in Trilogy-5!
#IMS26
@AlGarfall @MileHighMyeloma

[Suzanne Lentzsch, MD, PhD @SLentzsch]

@AuclairDan @NBahlis @Myeloma_Society Congratulations 🎊! Well deserved @NBahlis

[Meral Beksac @mbeksac56]

Remembering Robert Kyle - International Myeloma Society He has been a true legend in the field of myeloma. His multidimensional vision has structured our current concepts. He has been a role model for many leaders today. Rest in peace🙏 https://t.co/przKu75XJ2

[Columbia Med CME @CUIMCMedCME]

Advances in AL Amyloidosis: Biomarkers, Complications & Emerging Therapies — CME from @ColumbiaMed
Diagnosis, transplantation, and cell therapy

VIRTUAL
4.0 ACCME credits
October 30, 8:25am–12:30pm ET
Register: https://t.co/2Ae1QL4UaN
#Amyloidosis #Hematology

[Suzanne Lentzsch, MD, PhD @SLentzsch]

@CUIMCMedCME @ColumbiaMed Don't miss Advances in AL Amyloidosis: Biomarkers, Complications & Emerging Therapies — CME from @ColumbiaMedDiagnosis, transplantation, and cell therapy with @rajshekharucms as Course Director

[Raj Chakraborty @rajshekharucms]

With all the advances in relapsed #MultipleMyeloma in the past one year (from CARTITUDE-4 to TEC-3/9 and now TAL-6), it has become impossible to open RCTs in the 1-3 prior line space without CAR T/BsAb in the control arm (at least in the US). With not only PFS but also OS benefit with CAR T/BsAb in earlier lines, hard to justify randomizing patients in US to traditional triplets.

Glad that there is one such trial (Ram vs Tec) upcoming, and hopefully more in the future!

[Suzanne Lentzsch, MD, PhD @SLentzsch]

Happy July 4th!

[Suzanne Lentzsch, MD, PhD @SLentzsch]

@mbeksac56 @RahulBanerjeeMD @PlasmaCellPete Congratulations! Well deserved!

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

#mmsm #EHA26

MajesTEC-3 high risk post hoc analysis @RahulBanerjeeMD

Tec-Dara worked well in patients with 2HRCA or more as well as functionally high risk

Really good results in hard to treat patients

[Samuel Hume @DrSamuelBHume]

One of the most amazing things I’ve ever seen: a standing ovation for the full Daraxonrasib results

I feel inspired and energised, to put it mildly — we have a targeted therapy for pancreatic cancer now, and nothing is undruggable anymore

[Suzanne Lentzsch, MD, PhD @SLentzsch]

@awechalekar @columbiacancer Thank you Ashu for an outstanding presentation!

[Suzanne Lentzsch, MD, PhD @SLentzsch]

One of the most rewarding and emotional moments of my career took place at #ASCO2026. In 2015, I started the first-in-human trial of 11-1F4 (now anselamimab), supported by a small FDA grant and @columbiacancer. At the time, the path forward was far from certain. We faced limited funding, strong competition from Prothena’s NEOD001 program, and considerable skepticism from industry given the rarity of AL amyloidosis and the fact that competing programs were already much further advanced in development.

Despite these challenges, we continued to move forward step by step. The phase 1 study demonstrated encouraging results, ultimately leading to the founding and funding of Caelum Biosciences in 2017 and the launch of the subsequent phase 2 and phase 3 studies. Those efforts were later advanced and completed through the commitment and resources of @AlexionCARES and @AstraZenecaUS.

@ASCO I had the privilege of chairing the session when the final phase 3 results where presented by Dr. Wechalekar, which demonstrated a significant overall survival benefit in patients with stage IIIA/IIIB κ AL amyloidosis🙌. Seeing a scientific concept evolve from an investigator-initiated first-in-human study into a positive phase 3 trial is extraordinarily rewarding.

This achievement reflects the dedication of countless patients, supporters🙏@MorieGertz, investigators, research staff, industry partners, and advocates who believed in this program over many years. It is also a powerful reminder of why we do translational research-to transform promising science into therapies that meaningfully improve patients' lives.

#ASCO2026 #ALAmyloidosis @Amyloidosis_ARC @Amyloidosisfdn @AmyloidosisSupp @ISA_Amyloidosis

[Suzanne Lentzsch, MD, PhD @SLentzsch]

@VincentRK @columbiacancer Thanks so much Vincent!

[Suzanne Lentzsch, MD, PhD @SLentzsch]

@TheBianchiLab 🙏🙏🙏

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Randomized CARES trial of anti-fibril antibody anselamimab in AL #amyloidosis did not meet primary end point in overall population but improved all-cause mortality cardiovascular hospitalizations in patients with kappa AL: https://t.co/939temEkIR. #alsm

[Thanos Dimopoulos @thanosdimop]

With Suzanne Lentzsch and Marivi Mateos at the Journal of Clinical Oncology editorial board meeting during ASCO 2026

[Raj Chakraborty @rajshekharucms]

With #ASCO26 approaching, here are the potentially practice-changing abstracts in plasma cell disorders that caught my attention. I will update my thoughts as simultaneous publications are released for some of them🧵#MultipleMyeloma #Amyloidosis